Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • The Pharma 50

Pfizer launches trial for novel oral COVID-19 therapeutic

By Brian Buntz | March 23, 2021

PfizerAn experimental oral antiviral from Pfizer will be the focus of a Phase 1 study involving healthy adults.

Known as PF-07321332, the drug has shown promise during in vitro studies against SARS-CoV-2.

PF-07321332 belongs to a class of drugs known as protease inhibitors, which are commonly used to treat HIV/AIDS and hepatitis C. Protease inhibitors bind to a viral enzyme known as protease to stop viral replication.

Pfizer believes PF-07321332 to be the first orally-administered SARS-CoV-2-specific investigational protease inhibitor to be studied in a clinical trial.

Pfizer is also researching an intravenous protease inhibitor, PF-07304814, for hospitalized COVID-19 patients in a Phase 1b trial.

The most recent trial involving the oral antiviral candidate PF-07321332 will administer multiple ascending doses to evaluate the drug’s safety and tolerability.

Pfizer says the antiviral also has potential in battling other coronaviruses in addition to SARS-CoV-2.

If it ultimately wins regulatory authorization, the drug could be administered quickly at the onset of COVID-19 infection to support the immune system. “We have designed PF-07321332 as a potential oral therapy that could be prescribed at the first sign of infection, without requiring that patients are hospitalized or in critical care,” said Dr. Mikael Dolsten, chief scientific officer and president, worldwide research, development and medical of Pfizer.

The drug could also be administered to hospitalized patients, Dolsten said in a statement.


Filed Under: clinical trials, Drug Discovery, Infectious Disease
Tagged With: coronavirus, covid-19, PF-07321332, Pfizer, SARS-CoV-2
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

Lab facility
Massachusetts is competing for ARPA-H biomedical research center
Blockchain
Startup vies to get blockchain adoption in pharma off the ground
Janssen
Janssen’s company group chairman dishes on growth strategy
Curebase
Curebase raises $40 million in Series B funding round 

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • The Pharma 50